Company

About

BeiCell Therapeutics

BeiCell Therapeutics

海淀区永嘉北路4号院一号楼 中关村科学城星谷, Beijing, CN

BeiCell Therapeutics is a revolutionary cell therapy company stemming from Prof. Hongkui Deng's lab at Peking University, aiming to provide completely off-the-shelf cell therapy for cancer, autoimmune diseases treatment and regenerative medicine.

CellOrigin Biotech

CellOrigin Biotech

Hangzhou, Zhejiang

CellOrigin Biotech has a long term focus on iPSC-derived innate immune cells and its applications in new cancer immune cells. Dr. Jin Zhang, the scientific co-founder of CellOrigin used to be trained as a research fellow at the Boston Children’s Hospital and Harvard Medical School. His team worked closely with clinicians at the First Affiliated Hospital of Zhejiang University and for the first time reported the induced pluripotent stem cell or iPSC-derived CAR-macrophages (CAR-iMac), and its applications in cancer immunotherapies. As for now, CellOrigin Biotech holds its proprietary technologies for iPSC-derived CAR-Macrophage. With this platform, they are collaborating with research groups in genome engineering and synthetic biology at Harvard and MIT to fully unleash the potential of iPSC-derived immune cells, which are highly editable, expandable and clonal. Eventually, they would like to achieve a goal of bring more effective, universal and safe immune cell products to cancer patients, especially for those with solid tumors. The investigator initiated trials has been initiated at the First Hospital of Zhejiang University. The core proprietary technology platform and the core patents including the engineered macrophages from pluripotent stem cells has been authorized and is in the process of entering the US, Australia, South Africa, etc.

Epigenic Therapeutics

Epigenic Therapeutics

Shanghai, China

Epigenic Therapeutics is a frontier biotechnology company dedicated to developing next generation gene editing therapy utilizing regulation of epigenetic genome for a variety of diseases. Founded in 2021 by leading scientists focused on discovering gene editing technologies and developing gene editing therapies, the company has multiple product candidates in the pipeline, including treatment for metabolic, cardiovascular, viral hepatitis, ocular and rare diseases.

Great Bay Bio

Great Bay Bio

Unit 518 of the 5th Floor of Building 11W, Phase Two, Hong Kong Science Park, Pak Shek Kok, New Territories, Hong Kong, China

Great Bay Bio (GBB), based in Hong Kong, is an innovative biotech company with a vision of Disruptive Revolution of Biologics Development. Committed to utilizing AI and other cutting-edge technologies, GBB aims to address the challenges of long timelines, high costs, and low success rates in drug development, and in industries involving bioprocessing, e.g., synthetic biology, IVD and CGT. Led by a team of experienced professionals in biopharmaceuticals and AI, GBB's members boast over 20 successful IND filings approved by both China and the United States. GBB has launched multiple proprietary AI biotech platforms; AlfaCell, an AI-enabled site-specific integration cell line development platform that resolves multiple developmental bottlenecks, including unpredictable cell line stability and labor-intensive screening during CLD. Additionally, the AlfaMedX platform is an AI-enabled cell culture media development platform, responsible for creating over 50 unique cell culture media that outperform commercially available CHO cell culture media. GBB has secured 40+ patent applications, related to AI-enabled biological platform. Recognizing the potential of these platforms, GBB has formed partnerships with over 20 leading domestic and international companies.

HemaCell (Xueji Biotechnology)

HemaCell (Xueji Biotechnology)

5th Floor, Building 5, Zone B, Phase V, Biomedical Industrial Park, No. 21 Dongyanli Road, Suzhou Industrial Park, Jiangsu Province, China

Xueji Bio is a stem cell biopharmaceutical company founded by overseas returnees. It is committed to regenerating blood cells through stem cells for cell therapy of various diseases and related drug research and development. The company's founding members are from famous universities at home and abroad, such as Stanford University, Harvard University, and Peking University. Based on the world's leading stem cell directed differentiation system, Xueji Bio uses in vitro produced platelets as its lead product to address the urgent need for platelets in diseases such as cancer, liver disease, critical illness, and blood diseases, as well as develop innovative drugs for various platelet abnormality-related diseases.

Hillgene Biopharma

Hillgene Biopharma

SUZHOU, JIANGSU 215000, CN

Jiangsu Hillgene BioPharma is a leading CDMO platform for cell therapeutics. Our shareholders include China SME Development Fund, Guokejiahe Fund, Haier Capital, Huapont life science, China Capital Management, etc. The company is headquartered in Wuzhong District of Suzhou, the beautiful shore of Taihu Lake, with a registered capital of 100 million RMB. At present, a nationwide network of production bases has been formed initially, consisting of the headquarters in Suzhou (10000m2 GMP facility constructed) and the production base in Shenzhen (8000m2 GMP facility under construction). Meanwhile, the production base in North Carolina that is under construction contributes to the global layout     Hillgene focuses on cell therapeutics' and  particular plasmid production platforms, suspended and serum-free culture of viruses, and fully enclosed process development of cells, providing one-stop services from discovery to product delivery. We have helped several partners successfully develop drugs including CAR-T, TCR-T, and stem cells. And we are dedicated to pushing more projects to a new milestone quickly and bringing more cell therapy drugs into the market to let patients enjoy the products. Cell therapy innovation inspired.

Hopstem Biotechnology Co., Ltd.

Hopstem Biotechnology Co., Ltd.

Hangzhou, CN

Hopstem Bioengineering Co., Ltd. was founded on January 2017 in Hangzhou, by neuroscientists and stem cell biologists from Johns Hopkins University. Hopstem has established world-leading iPSCs platform of neural differentiation and cell engineering. Hopstem has developed several critical patented technologies,as well as CMC platform for iPSC-derived cell therapy products. Hopstem has iPSC reprogramming patent, GMP iPSC line with global licensing rights, iPSC-derived cell product manufacturing and quality system, and a variety of cell therapy products and pipelines, targeting CNS diseases, optical diseases and tumor. Hopstem’s first clinical product - neural progenitor cell hNPC01 targets neural injury diseases such as stroke and traumatic brain injury, has received China's IND approval and entered clinical trials. Hopstem is committed to translating the most cutting-edge technologies to provide global patients with safe, efficient and affordable cell therapy products.

Jiangsu Hillgene Biopharma Co.

Jiangsu Hillgene Biopharma Co.

Suzhou, Jiangsu, China

Neukio Biotherapeutics

Neukio Biotherapeutics

Shanghai, China

Neukio Biotherapeutics focuses on development of next generation allogenic cell therapies via the iPSC-CAR-NK axis, through internal discovery and external collaboration, with emphasis on innovative immuno-oncology products.

Pregene Biopharma

Pregene Biopharma

Shenzhen, China

Shenzhen Pregin Biopharmaceutical Co., Ltd. is a national high-tech enterprise, Guangdong Provincial Cell and Gene Therapy Innovative Drug Engineering Technology Research Center, and Shenzhen Special New Enterprise. Investor shareholders include the National Small and Medium Enterprises Development Fund and the National Science and Technology Commission of the Chinese Academy of Sciences. Jiahe Fund, Haier Capital, Shenzhen Capital Group, Winbond Health ( 002004), etc. It has been deeply involved in the field of cell and gene therapy drugs for many years.

UniXell Biotechnology

UniXell Biotechnology

Shanghai, China